Milnace (Savella)50mg – 100 tablet


Each Milnace contains 50 mg Milnacipran HCL 100 tablets used to treat the symptoms of depression and other pain disorders.

ATC Classification: N06AX17
Active Ingrediant: Milnacipran HCL
Generic Name: Milnace
Manufacturer: Torrent Pharma
Strength: 50mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 100 Tab


Medication Safety Issues

Sound-alike/look-alike issues:

Milnacipran may be confused with levomilnacipran

Savella may be confused with cevimeline, sevelamer

Geriatric Patients: High-Risk Medication:

Beers Criteria: Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) are identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2019]).


Generic Available (US)




Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).


Adverse Reactions


Central nervous system: Headache (18%), insomnia (12%)

Endocrine & metabolic: Hot flash (12%)

Gastrointestinal: Nausea (37%), constipation (16%)

1% to 10%:

Cardiovascular: Palpitations (7%), increased heart rate (6%), hypertension (5%), flushing (3%), increased blood pressure (3%), tachycardia (2%), peripheral edema (≥1%)

Central nervous system: Dizziness (10%), migraine (5%), chills (2%), depression (≥1%), drowsiness (≥1%), falling (≥1%), fatigue (≥1%), irritability (≥1%)

Dermatologic: Hyperhidrosis (9%), skin rash (3%), night sweats (≥1%)

Endocrine & metabolic: Decreased libido (≥2%), hypercholesterolemia (≥1%), weight changes (≥1%)

Gastrointestinal: Vomiting (7%), xerostomia (5%), abdominal pain (3%), decreased appetite (2%), abdominal distension (≥1%), diarrhea (≥1%), dysgeusia (≥1%), dyspepsia (≥1%), flatulence (≥1%), gastroesophageal reflux disease (≥1%)

Genitourinary: Decreased urine output (≥2%), dysuria (≥2%), ejaculation failure (≥2%), ejaculatory disorder (≥2%), erectile dysfunction (≥2%), prostatitis (≥2%), scrotal pain (≥2%), testicular pain (≥2%), testicular swelling (≥2%), urethral pain (≥2%), urinary hesitancy (≥2%), urinary retention (≥2%), cystitis (≥1%), urinary tract infection (≥1%)

Neuromuscular & skeletal: Tremor (2%)

Ophthalmic: Blurred vision (2%)

Respiratory: Dyspnea (2%)

Miscellaneous: Fever (≥1%)

<1%, postmarketing, and/or case reports: Accommodation disturbance, acute pancreatitis, acute renal failure, aggressive behavior, angle-closure glaucoma, anorexia, cardiomyopathy (takotsubo), delirium, erythema multiforme, galactorrhea, hallucination, hepatitis, homicidal ideation, hyperprolactinemia, hypertensive crisis, hyponatremia, leukopenia, loss of consciousness, neuroleptic malignant syndrome (Stevens 2008), neutropenia, outbursts of anger, parkinsonian-like syndrome, Raynaud phenomenon (Khouri 2016; Peiró 2007), rhabdomyolysis, seizure, serotonin syndrome, Stevens-Johnson syndrome, supraventricular tachycardia, thrombocytopenia

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , ,


Dosage Type

Packaging Type

Shipping From


Torrent Pharma


There are no reviews yet.

Be the first to review “Milnace (Savella)50mg – 100 tablet”

Your email address will not be published. Required fields are marked *